If you're a doctor, you probably had some insight into what an incredibly popular phenomenon GLP-1 drugs would be before ... commercial real estate. In CRE, I think I can discern what's true ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

LifeVantage (LFVN) announced the completion of an international in vitro cell study that investigated the effects of its international ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Realistically, there’s a good chance your patients are using them to get GLP-1 agonists. And sometimes Ro’s practice will resort to using compounding pharmacies too, only if all other options ...

Lexaria Bioscience (LEXX) provided progress updates on its Phase 1b, 12-week chronic study GLP-1-H24-4 underway in Australia. Lexaria has ...

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 user are significantly reducing their grocery spending. The paper ...

However, a new class of medications, GLP-1 agonists, originally designed for diabetes and obesity management, shows promise as a revolutionary tool in addiction treatment. GLP-1, or glucagon-like ...